RICHMOND, Calif., Jan. 4, 2019 /PRNewswire/
-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today
that interim clinical data from the Company's inherited metabolic
diseases development programs will be presented at
WORLDSymposium, an annual conference dedicated to lysosomal
diseases being held February
4-8th, 2019 at the Hyatt Regency Orlando in
Orlando, Florida.
The WORLDSymposium program includes two platform
presentations from clinical trials of Sangamo's zinc finger
nuclease (ZFN)-mediated in vivo genome editing product
candidates, SB-318 and SB-913, which are being evaluated for the
treatment of mucopolysaccharidosis type I (MPS I) and type II (MPS
II), respectively:
- "CHAMPIONS: A Phase 1/2 clinical trial with dose escalation of
SB-913 ZFN-mediated in vivo human genome editing for
treatment of MPS II (Hunter syndrome)"
Presenter: Joseph Muenzer, M.D.,
Ph.D., University of North Carolina
School of Medicine
February 7th, 2019 at
11:00 a.m. Eastern Time
- "EMPOWERS: A Phase 1/2 clinical trial of SB-318 ZFN-mediated
in vivo human genome editing for treatment of MPS I (Hurler
Syndrome)"
Presenter: Paul Harmatz, MD, UCSF
Benioff Children's Hospital Oakland
February 7th, 2019 at
11:15 a.m. Eastern Time
The SB-913 (MPS II) presentation is expected to include interim
data on safety and biochemical measurements at up to 24 weeks from
six subjects enrolled in the three dose cohorts of the CHAMPIONS
Study. The SB-318 (MPS I) presentation is expected to describe the
scientific rationale for SB-318, the clinical trial design, and
preliminary safety and biochemical measurements at up to four weeks
from the first three patients enrolled in the EMPOWERS Study.
Sangamo expects to provide additional SB-913 and SB-318 updates
in 2019 as data accumulate and mature in these clinical development
programs.
About Sangamo Therapeutics
Sangamo
Therapeutics, Inc. is focused on translating ground-breaking
science into genomic medicines with the potential to transform
patients' lives using the Company's platform technologies in genome
editing, gene therapy, gene regulation and cell therapy. For more
information about Sangamo, visit www.sangamo.com.
Forward-Looking Statements
This press release may
contain forward-looking statements based on Sangamo's current
expectations. These forward-looking statements include, without
limitation, references to presenting at the WORLDSymposium annual
conference and the types of data expected to be disclosed at the
WORLDSymposium. These statements are not guarantees of
future performance and are subject to certain risks, uncertainties
and assumptions that are difficult to predict. Factors that could
cause actual results to differ include, but are not limited to, the
dependence on the timing and success of clinical trials of lead
programs, the lengthy and uncertain regulatory approval process,
uncertainties related to the initiation, enrollment and completion
of clinical trials, including the CHAMPIONS study and the EMPOWERS
study, whether the final results from the EMPOWERS study and
CHAMPIONS study will validate and support the interim results and
the overall safety and efficacy of SB-318 and SB-913, respectively,
Sangamo's reliance on partners and other third-parties to meet
their clinical and manufacturing obligations, and the ability to
maintain strategic partnerships. Actual results may differ from
those projected in forward-looking statements due to risks and
uncertainties that exist in Sangamo's operations and business
environments. These risks and uncertainties are described more
fully in Sangamo's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2018 as filed
with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Sangamo undertakes no duty to update such information except as
required under applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-announces-upcoming-clinical-data-presentations-at-worldsymposium-2019-300772883.html
SOURCE Sangamo Therapeutics, Inc.